March 15, 2026 a 03:43 pm

GILD: Fundamental Ratio Analysis - Gilead Sciences, Inc.

Gilead Sciences, Inc. Stock Analysis

Gilead Sciences, Inc. has a strong position in the biopharmaceutical sector with its innovative treatments in HIV/AIDS and liver diseases. Recent fundamental analysis shows promising scores, indicating stability and growth potential. However, the debt-to-equity ratio remains a concern, necessitating careful monitoring.

Fundamental Rating

The current fundamental data suggests strong performance in key areas, though there is room for improvement in debt management.

Category Score Visualization
Overall Score 3
Discounted Cash Flow 4
Return on Equity 5
Return on Assets 5
Debt to Equity 1
Price to Earnings 2
Price to Book 1

Historical Rating

Comparing the recent scores with past data illustrates stability in core areas while pointing to possible challenges in debt management.

Date Overall DCF ROE ROA D/E P/E P/B
2026-03-13 3 4 5 5 1 2 1
N/A 0 4 5 5 1 2 1

Analyst Price Targets

Analysts' estimates reflect a strong upside potential, though varying perspectives underscore the need for careful consideration of market risks.

High Low Median Consensus
$180 $105 $162 $158.71
Gilead Sciences Stock Chart

Analyst Sentiment

The sentiment among analysts is predominantly positive, with a majority recommending a 'Buy' stance, reflecting confidence in the company's future prospects.

Recommendation Count Distribution
Strong Buy 0
Buy 37
Hold 20
Sell 1
Strong Sell 0

Conclusion

Gilead Sciences, Inc. features a solid portfolio in the biopharmaceutical industry, with strong financial fundamentals and favorable analyst projections. Despite its robust return metrics, attention is imperative due to its suboptimal debt-to-equity ratio. While mainly seen as a 'Buy', risk factors, including market volatility and strategic execution, should be closely monitored to mitigate potential downsides.